The medical community is carefully watching the novel dual-action agent, a unique therapy targeting both glucagon-like peptide-1 and GIP. Early trials suggest it may offer meaningful improvements in reducing body weight compared to available therapies, potentially representing a important step forward in the management synedica retatrutide of obesi